|
|
Article: Boulder, Colo., Biotechnology Firm Brings Up Losses from 1997.
- Article from:
- Knight Ridder/Tribune Business News
- Article date:
- March 10, 1999
- Author:
CopyrightCOPYRIGHT 1999 Knight-Ridder/Tribune Business News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Knight Ridder/Tribune Business News
Mar. 10 -- NeXstar Pharmaceuticals Inc. inched closer toward profitability. Its new parent company, Gilead Sciences Inc., will reap the benefits of that accomplishment.
The company (Nasdaq: NXTR) reported 1998 earnings of $10.9 million, or 38 cents per share, compared with a loss of $43.9 million, or $1.65 per share. NeXstar attributes its turnaround to a non-recurring gain of $22.1 million, or 78 cents per share, related to the sale of 51 percent to SKW Americas Inc. of Proligo LLC, NeXstar's specialty chemical manufacturing subsidiary.
The company, however, is still operating in the red. For 1998, it had an ...